LLY - Eli Lilly & Company

-

$undefined

N/A

(N/A)

Eli Lilly & Company NYSE:LLY Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Location: Lilly Corporate Center, Indianapolis, IN, 46285, United States | Website: https://www.lilly.com | Industry: Drug Manufacturers - General | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

684.1B

Cash

3.222B

Avg Qtr Burn

N/A

Short % of Float

0.82%

Insider Ownership

0.16%

Institutional Own.

84.03%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Jardiance® (empagliflozin) (anti-SGLT2) Details
Diabetes, Type 2 diabetes, Chronic kidney disease

Approved

Quarterly sales

Jaypirca (pirtobrutinib) Details
Blood cancer, Cancer, Lymphoma, Mantle cell lymphoma

Approved

Quarterly sales

Approved

Quarterly sales

EBGLYSS™ (lebrikizumab-lbkz) Details
Skin disease/disorder, Atopic dermatitis

Approved

Quarterly sales

Jaypirca® Pirtobrutinib Details
Cancer, Chronic lymphocytic leukemia, Lymphoma, Blood cancer, Small lymphocytic lymphoma

Approved

Quarterly sales

Zepbound (Tirzepatide) Details
Obstructive sleep apnea , Sleeping disorder

Approved

Quarterly sales

Approved

Quarterly sales

Approved

Quarterly sales

Kisunla (Donanemab) Details
Alzheimer's disease

Approved

Quarterly sales

Phase 3

Data readout

Retevmo +/- pembrolizumab Details
Non-small cell lung carcinoma

Phase 3

Data readout

Abemaciclib Details
Castration-resistant prostate cancer

Phase 3

Data readout

Remternetug Details
Alzheimer's disease

Phase 3

Data readout

Phase 3

Data readout

Phase 3

Data readout

Pirtobrutinib Details
Blood cancer, Cancer, Lymphoma, Chronic lymphocytic leukemia

Phase 3

Data readout

Tirzepatide Details
Heart failure, Obesity

Phase 3

Update

Orforglipron Details
Type 1 diabetes

Phase 3

Update

Phase 3

Update

Phase 3

Update

Retevmo Details
Medullary Thyroid Cancer

Phase 3

Update

Phase 3

Initiation

Phase 2b

Data readout

Phase 2b

Update

Phase 2b

Initiation

Tirzepatide Details
metabolic dysfunction-associated steatohepatitis , Liver fibrosis

Phase 2

Update

Peresolimab /LY3462817 Details
Autoimmune disease, Rheumatoid arthritis

Phase 2

Update

Phase 2

Update

Phase 2

Update

Phase 1/2

Data readout

LY4170156 Details
Advanced ovarian cancer, solid tumor/s

Phase 1

Data readout

Phase 1

Data readout

DC-853 Details
Inflammatory disease, Autoimmune disease

Phase 1

Update

AK-OTOF Details
OTOF-mediated hearing loss

Phase 1

Update